Human Gene Therapy Clinical Development最新文献_第3页

Response to MacLaren et al., re: Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 Mice. Hum Gene Ther Clin Dev 2018;29(4):188-197. 对MacLaren等人的回应:表达密码子优化的RPGR的AAV载体在rgr缺陷的Rd9小鼠中的毒理学和药理学。中华医学杂志，2018;29(4):188-197。

Human Gene Therapy Clinical Development Pub Date : 2019-03-01 DOI: 10.1089/humc.2019.29042.gjy

Guo-Jie Ye, Chunjuan Song, Jeff Chulay, Mark Shearman

引用次数: 0

Gene Therapy Briefs. 基因治疗简报。

Human Gene Therapy Clinical Development Pub Date : 2019-03-01 DOI: 10.1089/humc.2019.29043.bfs

Alex Philippidis

引用次数: 0

A Birds-Eye View: An Interview with Nick Leschly. 鸟瞰:采访尼克·莱斯利。

Human Gene Therapy Clinical Development Pub Date : 2019-03-01 DOI: 10.1089/humc.2019.29044.int

James M Wilson

引用次数: 0

Re: Song et al., Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 Mice. Hum Gene Ther Clin Dev 2018; 29(4):188-197. Re: Song等，表达密码子优化RPGR的AAV载体对rgr缺陷小鼠的毒理学和药理学研究。Hum Gene Ther clindev 2018;29(4): 188 - 197。

Human Gene Therapy Clinical Development Pub Date : 2019-03-01 DOI: 10.1089/humc.2019.29041.rem

Robert E MacLaren, M Dominik Fischer, Cristina Martinez-Fernandez De La Camara

引用次数: 0

A Gene Therapy Approach to Improve Copper Metabolism and Prevent Liver Damage in a Mouse Model of Wilson Disease. 改善肝豆状核变性小鼠模型铜代谢和预防肝损伤的基因治疗方法

Human Gene Therapy Clinical Development Pub Date : 2019-03-01 Epub Date: 2019-02-25 DOI: 10.1089/humc.2018.219

Jenny A Greig, Jayme M L Nordin, Melanie K Smith, Scott N Ashley, Christine Draper, Yanqing Zhu, Peter Bell, Elizabeth L Buza, James M Wilson

{"title":"A Gene Therapy Approach to Improve Copper Metabolism and Prevent Liver Damage in a Mouse Model of Wilson Disease.","authors":"Jenny A Greig, Jayme M L Nordin, Melanie K Smith, Scott N Ashley, Christine Draper, Yanqing Zhu, Peter Bell, Elizabeth L Buza, James M Wilson","doi":"10.1089/humc.2018.219","DOIUrl":"https://doi.org/10.1089/humc.2018.219","url":null,"abstract":"Wilson disease (WD), an autosomal recessive disease caused by mutations in a copper-transporting P-type ATPase (Atp7b), causes severe liver damage. This disease is currently treated with the lifelong use of copper chelation therapy, which has side effects and does not fix copper metabolism. Here, we thoroughly characterized a mouse model of WD, the toxic milk mouse, and used the model to test a gene therapy approach for treating WD. WD mice accumulated copper in the liver from birth; severe copper accumulation and concurrent liver disease were evident by 2 months of age. Intravenously administering an adeno-associated viral (AAV) 8 vector expressing a codon-optimized version of the human ATP7B transgene into 2-month-old WD mice significantly decreased liver copper levels compared with age-matched, uninjected, WD mice. We also observed a significant dose-dependent decrease in liver disease. Male mice injected with 1011 genome copies of AAV8 vector showed only mild histopathological findings with a complete lack of liver fibrosis. Therefore, we conclude that administering gene therapy at the early stages of disease onset is a promising approach for reducing liver damage and correcting copper metabolism in WD.","PeriodicalId":51315,"journal":{"name":"Human Gene Therapy Clinical Development","volume":"30 1","pages":"29-39"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/humc.2018.219","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36908194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Gene Therapy Entering the Land of Oz. 基因疗法进入奥兹国。

Human Gene Therapy Clinical Development Pub Date : 2018-12-01 DOI: 10.1089/humc.2018.29040.wil

James M Wilson

引用次数: 0

Establishing China's National Standard for the Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine (Ad5-EBOV) Virus Titer. 建立重组腺病毒5型载体型埃博拉疫苗(Ad5-EBOV)病毒滴度中国国家标准。

Human Gene Therapy Clinical Development Pub Date : 2018-12-01 Epub Date: 2018-12-04 DOI: 10.1089/humc.2018.129

Yuhua Li, Ling Wang, Tao Zhu, Shipo Wu, Liqiang Feng, Ping Cheng, Jingjing Liu, Junzhi Wang

{"title":"Establishing China's National Standard for the Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine (Ad5-EBOV) Virus Titer.","authors":"Yuhua Li, Ling Wang, Tao Zhu, Shipo Wu, Liqiang Feng, Ping Cheng, Jingjing Liu, Junzhi Wang","doi":"10.1089/humc.2018.129","DOIUrl":"https://doi.org/10.1089/humc.2018.129","url":null,"abstract":"The 2014 Ebola outbreak in West Africa brought great threat to public health worldwide. There was no approved antiviral therapy or vaccine available to control the disease at that time. Several kinds of Ebola vaccines were urgently under development across the world. Among these, the novel recombinant adenovirus type 5 vector-based Ebola vaccine (Ad5-EBOV)-the first Ebola vaccine based on the 2014 Zaire Guinea epidemic strain-was developed in China, and its safety and immunogenicity were demonstrated in China and Sierra Leone. The license to market the drug was approved on October 19, 2017, by the Chinese Food and Drug Administration. In order to standardize the test on the Ad5-EBOV virus titer, China's national standard substance for the virus titer of Ad5-EBOV was established according to the recommendations for the preparation, characterization, and establishment of international and other biological reference standards from the World Health Organization and Chinese Pharmacopoeia (third edition). The standard for the Ad5-EBOV virus titer was prepared with a volume of 0.5 mL per ampoule in lyophilized form. The samples of the standard, designated as A, B, C, D with different aims, were blinded and distributed to five laboratories to be collaboratively calibrated. The virus titer for this standard was determined with the antibody staining method according to the instructions in the Adeno-X™ Rapid Titer Kit. The homogeneity and stability of the standard substance were also satisfied. The virus titer standard value was 8.54 lg infectious units (IFU)/mL, and the 95% confidence interval was between 7.94 lg IFU/mL and 9.14 lg IFU/mL. This standard was approved by the Chinese national committee and is available on the National Institutes for Food and Drug Control Web site ( www.nifdc.org.cn ; lot no. 250019-201501).","PeriodicalId":51315,"journal":{"name":"Human Gene Therapy Clinical Development","volume":"29 4","pages":"226-232"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/humc.2018.129","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36679885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Gene Therapy Briefs. 基因治疗简报。

Human Gene Therapy Clinical Development Pub Date : 2018-12-01 DOI: 10.1089/humc.2018.29039.bfs

Alex Philippidis

引用次数: 0

Ultrasound-Targeted Microbubble Destruction Delivery of Insulin-Like Growth Factor 1 cDNA and Transforming Growth Factor Beta Short Hairpin RNA Enhances Tendon Regeneration and Inhibits Scar Formation In Vivo. 超声靶向微泡破坏传递胰岛素样生长因子1 cDNA和转化生长因子β短发夹RNA促进肌腱再生并抑制体内瘢痕形成

Human Gene Therapy Clinical Development Pub Date : 2018-12-01 Epub Date: 2018-10-25 DOI: 10.1089/humc.2018.121

Xi Xiang, Qianying Leng, Yuanjiao Tang, Liyun Wang, Jianbo Huang, Yi Zhang, Li Qiu

{"title":"Ultrasound-Targeted Microbubble Destruction Delivery of Insulin-Like Growth Factor 1 cDNA and Transforming Growth Factor Beta Short Hairpin RNA Enhances Tendon Regeneration and Inhibits Scar Formation In Vivo.","authors":"Xi Xiang, Qianying Leng, Yuanjiao Tang, Liyun Wang, Jianbo Huang, Yi Zhang, Li Qiu","doi":"10.1089/humc.2018.121","DOIUrl":"https://doi.org/10.1089/humc.2018.121","url":null,"abstract":"Ultrasound-targeted microbubble destruction (UTMD), which has been successfully used for the treatment of many diseases, offers a promising noninvasive approach for target-specific gene delivery. This study investigated the UTMD delivery of insulin-like growth factor 1 (IGF-1) cDNA and transforming growth factor beta (TGF-β) short hairpin RNA for Achilles tendon injury in rats. Briefly, 168 rats with an injured Achilles tendon were randomly divided into seven groups: (1) IGF-1 + UTMD, (2) TGF-β + UTMD, (3) IGF-1 + TGF-β + UTMD, (4) control, (5) IGF-1, (6) TGF-β, and (7) IGF-1 + TGF-β. At 2, 4, 8, and 12 weeks post treatment, six rats from each group were euthanized. IGF-1 expression and TGF-β expression were evaluated using an adhesion index score, pathological examination, quantitative real-time reverse transcription polymerase chain reaction, Western blotting, and biomechanical measurement. The lowest adhesion index score, the lightest inflammation, the highest 4,6-diamidino-2-phenylindole nuclear counter signals, the highest IGF-1 expression, and the lowest TGF-β expression were observed in group 3 (p < 0.05). Furthermore, higher expression of IGF-1 mRNA was observed in groups 1 and 3, while lower expression of TGF-β mRNA was observed in groups 2 and 3 (p < 0.05). The UTMD groups showed a higher transfection efficiency than the groups without UTMD. Downregulation of type III collagen and upregulation of type I collagen were observed in groups 1-3. Moreover, during weeks 4, 8, and 12, greater maximum load and tensile stress were observed in group 3 compared to the other groups (p < 0.05), while the highest tendon stiffness was observed in week 12 (p < 0.05). To conclude, the results suggest that UTMD delivery of IGF-1 and TGF-β offers a promising treatment approach for tendon injury in vivo.","PeriodicalId":51315,"journal":{"name":"Human Gene Therapy Clinical Development","volume":"29 4","pages":"198-213"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/humc.2018.121","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36660755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Varinostat Alters Gene Expression Profiles in Aortic Tissues from ApoE^-/- Mice. Varinostat改变ApoE-/-小鼠主动脉组织基因表达谱

Human Gene Therapy Clinical Development Pub Date : 2018-12-01 Epub Date: 2018-11-12 DOI: 10.1089/humc.2018.141

Yicong Ye, Xiliang Zhao, Yiyun Lu, Bo Long, Shuyang Zhang

{"title":"Varinostat Alters Gene Expression Profiles in Aortic Tissues from ApoE-/- Mice.","authors":"Yicong Ye, Xiliang Zhao, Yiyun Lu, Bo Long, Shuyang Zhang","doi":"10.1089/humc.2018.141","DOIUrl":"https://doi.org/10.1089/humc.2018.141","url":null,"abstract":"Atherosclerosis (AS) is a complex, chronic inflammatory disease that is characterized by plaque buildup within arterial vessel walls. Preclinical trials have suggested that vorinostat, a pan-histone deacetylase inhibitor (HDACi), reduces vascular inflammation and AS, but the underlying protective mechanism has not been fully elucidated. The present study aimed to identify altered gene expression profiles in aortic tissues from ApoE-/- mice after vorinostat treatment. Male ApoE-/- mice fed a high-fat diet were treated with either vorinostat or vehicle, and the aortic plaque area was quantified 8 weeks after treatment. Aortic tissues were collected from both the vorinostat group (n = 3) and vehicle group (n = 3) for deep sequencing of the cDNA to construct sRNA libraries. Oral administration of vorinostat significantly reduced plaque size in the ApoE-/- mice (p < 0.05). In total, 1,550 differentially expressed mRNAs, 56 differentially expressed miRNAs, and 381 differentially expressed lncRNAs were identified in the vorinostat group compared to the vehicle group. Subsequently, a global lncRNA-miRNA-mRNA triple network was constructed based on the competitive endogenous RNA (ceRNA) theory. The hepatitis C signaling pathway was significantly enriched among the differentially expressed mRNAs from the ceRNA network, which suggests that vorinostat has anti-inflammatory properties. Importantly, the identified target pair of mmu-miR-3075-5p/lncRNA-A330023F24Rik/Ldlr may regulate drug response. Upregulation of low-density lipid receptor (Ldlr) and lncRNA-A330023F24Rik and downregulation of mmu-miR-3075-5p were further verified by quantitative real-time polymerase chain reaction. To conclude, vorinostat reduced AS in ApoE-/- mice. Differentially expressed mRNA, lncRNAs, and miRNAs, as well as their interactions and pathways, were identified, which partially explain vorinostat's anti-atherosclerotic effects.","PeriodicalId":51315,"journal":{"name":"Human Gene Therapy Clinical Development","volume":"29 4","pages":"214-225"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/humc.2018.141","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36545347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8